Modality
Radioligand
MOA
PCSK9i
Target
CGRP
Pathway
Incretin
Cervical Ca
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
→ Feb 2026
Phase 3Current
NCT08470377
451 pts·Cervical Ca
2019-01→2025-12·Recruiting
NCT04245290
251 pts·Cervical Ca
2024-03→2026-02·Not yet recruiting
702 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-153mo agoPh3 Readout· Cervical Ca
2026-02-191mo agoPh3 Readout· Cervical Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2025-12-15 · 3mo ago
Cervical Ca
Ph3 Readout
2026-02-19 · 1mo ago
Cervical Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08470377 | Phase 3 | Cervical Ca | Recruiting | 451 | NT-proBNP |
| NCT04245290 | Phase 3 | Cervical Ca | Not yet recr... | 251 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |